Profiling plasma microRNA in nasopharyngeal carcinoma with deep sequencing

Clinical Chemistry

Volumn 60, Issue 5, 2014, Pages 773-782

  Wang, Hai Yun ^a,b   Yan, Li Xu ^a,c   Shao, Qiong ^a   Fu, Sha ^a   Zhang, Zi Chen ^a   Ye, Weimin ^b   Zeng, Yi Xin ^a   Shao, Jian Yong ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b KAROLINSKA INSTITUTE   (Sweden)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBONUCLEASE; MICRORNA; MICRORNA 103; MICRORNA 29A; MICRORNA 483 5P; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; GENE EXPRESSION; HIGH RISK POPULATION; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN TISSUE; MALE; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; RHINOPHARYNGITIS; RNA EXTRACTION; RNA SEQUENCE; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SURVIVAL PREDICTION;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, RNA; YOUNG ADULT;

EID: 84899513058     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.214213     Document Type: Article

References (35)

1. Duffy MJ. Clinical uses of tumor markers: A critical review. Crit Rev Clin Lab Sci 2001;38:225-62.
2. Duffy MJ. Role of tumor markers in patients with solid cancers: A critical review. Eur J Intern Med 2007;18:175-84.
3. Chen CY, Han F, Zhao C, Lu LX, Sun Y, Liu XF, Lu TX. Treatment results and late complications of 556 patients with locally advanced nasopharyngeal carcinoma treated with radiotherapy alone. Br J Radiol 2009;82:452-8.
4. Cortez MA, Calin GA. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther 2009;9:703-11.
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
6. Zhang X, Chen J, Radcliffe T, Lebrun DP, Tron VA, Feilotter H. An array-based analysis of microRNA expression comparing matched frozen and formalin-fixed paraffin-embedded human tissue samples. J Mol Diagn 2008;10:513-9.
7. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 2011;57:833-40.
8. Sengupta S, Den Boon JA, Chen IH, Newton MA, Stanhope SA, Cheng YJ, et al. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci U S A 2008;105:5874-8.
9. * microRNA in nasopharyngeal carcinoma. Int J Cancer 2013:133:79-87.
10. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009;361:1437-47.
11. Li X, Zhang Y, Ding J, Wu K, Fan D. Survival prediction of gastric cancer by a seven-microRNA signature. Gut 2010;59:579-85.
12. Morin RD, O'Connor MD, Griffith M, Kuchenbauer F, Delaney A, Prabhu AL, et al. Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. Genome Res 2008;18:610-21.
13. Audic S, Claverie JM. The significance of digital gene expression profiles. Genome Res 1997;7:986-95.
14. Gordon AD. Classification, 2nd Ed. London: Chapman and Hall/CRC 1999.
15. Murtagh F. A survey of recent advances in hierarchical-clustering algorithms. Comput J 1983;26:354-9.
16. Steyerberg EW, Eijkemans MJ, Harrell FE Jr, Habbema JD. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med 2000;19:1059-79.
17. Cho WC. MicroRNAs: Potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 2010;42:1273-81.
18. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.
19. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008;13:48-57.
20. Wang HY, Sun BY, Zhu ZH, Chang ET, To KF, Hwang JS, et al. Eight-signature classifier for prediction of nasopharyngeal carcinoma survival. J Clin Oncol 2011;29:4516-25.
21. Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol 2012;13:633-41.
22. Park G, Borkovich KA. Small RNA isolation and library construction for expression profiling of small RNAs from neurospora and fusarium using Illumina high-throughput deep sequencing. Methods Mol Biol 2012;883:155-64.
23. Watson JA, Bryan K, Williams R, Popov S, Vujanic G, Coulomb A, et al. MiRNA profiles as a predictor of chemoresponsiveness in Wilms' tumor blastema. PLoS One 2013;8:e53417.
24. Patterson EE, Holloway AK, Weng J, Fojo T, Kebebew E. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 2011;117:1630-9.
25. Scheffer AR, Holdenrieder S, Kristiansen G, Von Ruecker A, Muller SC, Ellinger J. Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol 2012.
26. Guo Y, Chen Z, Zhang L, Zhou F, Shi S, Feng X, et al. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res 2008;68:26-33.
27. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, et al. A microRNA targeting dicer for metastasis control. Cell 2010;141:1195-207.
28. Xu H, Cheung IY, Guo HF, Cheung NK. MicroRNA miR-29 modulates expression of immunoinhibitory molecule b7-h3: potential implications for immune based therapy of human solid tumors. Cancer Res 2009;69:6275-81.
29. Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, et al. MicroRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010;115:2630-9.
30. Gebeshuber CA, Zatloukal K, Martinez J. MiR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 2009;10:400-5.
31. Li T, Chen JX, Fu XP, Yang S, Zhang Z, Chen Kh H, Li Y. MicroRNA expression profiling of nasopharyngeal carcinoma. Oncol Rep 2011;25:1353-63.
32. Wong TS, Man OY, Tsang CM, Tsao SW, Tsang RK, Chan JY, et al. MicroRNA let-7 suppresses nasopharyngeal carcinoma cells proliferation through downregulating c-Myc expression. J Cancer Res Clin Oncol 2011;137:415-22.
33. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.
34. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982;247:2543-6.
35. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, Levy R. Prediction of survival in diffuse large-B-cell lymphoma on the basis of the expression of six genes. N Engl J Med 2004;350:1828-37.